← Back to Search

High-flow oxygen: Initial Therapy for Cancer

Phase 2
Waitlist Available
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age >/= 18 years
Diagnosis of cancer
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0 (baseline) minutes and at 10 minutes
Awards & highlights

Study Summary

This trial is testing different types of oxygen therapy to see if they can help cancer patients with shortness of breath. Researchers also want to know if these therapies can improve lung function and quality of life.

Eligible Conditions
  • Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0 (baseline) minutes and at 10 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0 (baseline) minutes and at 10 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Dyspnea Numeric Score Between 0 and 10 Minutes
Secondary outcome measures
Change in Modified Borg Scale Intensity Between 0 and 10 Minutes
Change in Modified Borg Scale Unpleasantness Between 0 and 10 Minutes

Trial Design

4Treatment groups
Active Control
Placebo Group
Group I: High-flow oxygen: Initial TherapyActive Control4 Interventions
4-Period crossover therapy where initial 10 minute breathing treatment with High-flow oxygen (HFOx) is followed by 3 different breathing therapies of Low-flow oxygen (LFOx), High-flow air (HFAir), and Low-flow air (LFAir) with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
Group II: Low-flow oxygen: Initial TherapyActive Control4 Interventions
4-Period crossover therapy where initial 10 minute breathing treatment with Low-flow oxygen (LFOx) is followed by 3 different breathing therapies of HFOx, HFAir, and LFAir with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
Group III: High-flow air: Initial TherapyPlacebo Group4 Interventions
4-Period crossover therapy where initial 10 minute breathing treatment with High-flow oxygen (LFOx) is followed by 3 different breathing therapies of HFOx, LFOx, and LFAir with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
Group IV: Low-flow air: Initial TherapyPlacebo Group4 Interventions
4-Period crossover therapy where initial 10 minute breathing treatment with Low-flow air (LFAir) is followed by 3 different breathing therapies of HFOx, LFOx, and HFAir with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,960 Previous Clinical Trials
1,803,240 Total Patients Enrolled
David Hui, MDStudy ChairThe University of Texas MD Anderson Cancer Center
15 Previous Clinical Trials
101,364 Total Patients Enrolled

Frequently Asked Questions

~3 spots leftby Mar 2025